SGHT vs. OFIX, BVS, IRMD, SIBN, SRDX, ATRC, MDXG, AORT, CATX, and SILK
Should you be buying Sight Sciences stock or one of its competitors? The main competitors of Sight Sciences include Orthofix Medical (OFIX), Bioventus (BVS), Iradimed (IRMD), SI-BONE (SIBN), Surmodics (SRDX), AtriCure (ATRC), MiMedx Group (MDXG), Artivion (AORT), Perspective Therapeutics (CATX), and Silk Road Medical (SILK). These companies are all part of the "surgical & medical instruments" industry.
Orthofix Medical (NASDAQ:OFIX) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, community ranking, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.
89.8% of Orthofix Medical shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 4.7% of Orthofix Medical shares are owned by insiders. Comparatively, 28.9% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Orthofix Medical had 2 more articles in the media than Sight Sciences. MarketBeat recorded 3 mentions for Orthofix Medical and 1 mentions for Sight Sciences. Orthofix Medical's average media sentiment score of 1.53 beat Sight Sciences' score of 0.23 indicating that Sight Sciences is being referred to more favorably in the news media.
Orthofix Medical has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.76, indicating that its stock price is 176% more volatile than the S&P 500.
Orthofix Medical presently has a consensus target price of $18.00, indicating a potential upside of 34.13%. Sight Sciences has a consensus target price of $4.70, indicating a potential downside of 31.49%. Given Sight Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Orthofix Medical is more favorable than Sight Sciences.
Orthofix Medical has a net margin of -16.64% compared to Orthofix Medical's net margin of -67.18%. Sight Sciences' return on equity of -14.24% beat Orthofix Medical's return on equity.
Sight Sciences has lower revenue, but higher earnings than Orthofix Medical. Sight Sciences is trading at a lower price-to-earnings ratio than Orthofix Medical, indicating that it is currently the more affordable of the two stocks.
Orthofix Medical received 396 more outperform votes than Sight Sciences when rated by MarketBeat users. Likewise, 61.80% of users gave Orthofix Medical an outperform vote while only 31.91% of users gave Sight Sciences an outperform vote.
Summary
Orthofix Medical beats Sight Sciences on 12 of the 18 factors compared between the two stocks.
Get Sight Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGHT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGHT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sight Sciences Competitors List
Related Companies and Tools
